November 9, 2024: Study Finds Ozempic May Lead to Muscle Loss A new study published in The Lancet medical journal found that semaglutide, the active ingredient in Ozempic, may lead to a higher rate of muscle mass loss compared with caloric-restricted weight loss
These impacts are especially noticeable in the first four to eight weeks of a patients GLP-1 weight loss journey, leading to issues like constipation, nausea, bloating, vomiting, and other gastrointestinal discomforts
Metabolic regulation involves peptide hormones that convey information related to nutrient availability, energy status, and internal signaling balance
Long-term outlook for anxiety and tirzepatide The long-term psychiatric effects of tirzepatide remain an active area of research
Long-term side effects become less about your stomach and more about other body systems adapting
However, when you are taking a prescription medication like semaglutide, it is natural to wonder if you are still eligible to sit in that donor chair